We've found
9,220
archived clinical trials in
HIV / AIDS
We've found
9,220
archived clinical trials in
HIV / AIDS
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Updated: 3/17/2016
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
Status: Enrolling
Updated: 3/17/2016
Click here to add this to my saved trials
Effects of IGF-I in HIV Metabolic Disease
Updated: 3/22/2016
Effects of Recombinant IGF-I in HIV Associated Metabolic Disease
Status: Enrolling
Updated: 3/22/2016
Effects of IGF-I in HIV Metabolic Disease
Updated: 3/22/2016
Effects of Recombinant IGF-I in HIV Associated Metabolic Disease
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Updated: 3/22/2016
Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Status: Enrolling
Updated: 3/22/2016
Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Updated: 3/22/2016
Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults
Updated: 3/22/2016
A Novel Therapy for Glucose Intolerance in HIV Disease
Status: Enrolling
Updated: 3/22/2016
Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults
Updated: 3/22/2016
A Novel Therapy for Glucose Intolerance in HIV Disease
Status: Enrolling
Updated: 3/22/2016
Click here to add this to my saved trials
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Updated: 3/23/2016
A Pilot Study to Assess the Downregulation of HIV-1 Associated Chronic Inflammation in Patients With Limited Immunologic Responses When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Status: Enrolling
Updated: 3/23/2016
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Updated: 3/23/2016
A Pilot Study to Assess the Downregulation of HIV-1 Associated Chronic Inflammation in Patients With Limited Immunologic Responses When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Status: Enrolling
Updated: 3/23/2016
Click here to add this to my saved trials
A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
Updated: 3/24/2016
An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects
Status: Enrolling
Updated: 3/24/2016
A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
Updated: 3/24/2016
An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects
Status: Enrolling
Updated: 3/24/2016
Click here to add this to my saved trials
Urban Health Study II
Updated: 3/25/2016
Finding, Testing and Treating High-Risk Probationers and Parolees With HIV
Status: Enrolling
Updated: 3/25/2016
Urban Health Study II
Updated: 3/25/2016
Finding, Testing and Treating High-Risk Probationers and Parolees With HIV
Status: Enrolling
Updated: 3/25/2016
Click here to add this to my saved trials
WHC+ (Women's Health CoOp PLUS)
Updated: 3/25/2016
Combination Prevention for Vulnerable Women in South Africa
Status: Enrolling
Updated: 3/25/2016
WHC+ (Women's Health CoOp PLUS)
Updated: 3/25/2016
Combination Prevention for Vulnerable Women in South Africa
Status: Enrolling
Updated: 3/25/2016
Click here to add this to my saved trials
WHC+ (Women's Health CoOp PLUS)
Updated: 3/25/2016
Combination Prevention for Vulnerable Women in South Africa
Status: Enrolling
Updated: 3/25/2016
WHC+ (Women's Health CoOp PLUS)
Updated: 3/25/2016
Combination Prevention for Vulnerable Women in South Africa
Status: Enrolling
Updated: 3/25/2016
Click here to add this to my saved trials
HIV/AIDS, Severe Mental Illness and Homelessness
Updated: 3/30/2016
HIV/AIDS, Severe Mental Illness and Homelessness
Status: Enrolling
Updated: 3/30/2016
HIV/AIDS, Severe Mental Illness and Homelessness
Updated: 3/30/2016
HIV/AIDS, Severe Mental Illness and Homelessness
Status: Enrolling
Updated: 3/30/2016
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Click here to add this to my saved trials
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Updated: 3/30/2016
A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults
Status: Enrolling
Updated: 3/30/2016
Click here to add this to my saved trials
Eliciting Affect in Teens in a Virtual World (Project AVATAR)
Updated: 4/5/2016
Eliciting Affect in Teens in a Virtual World (Project AVATAR)
Status: Enrolling
Updated: 4/5/2016
Eliciting Affect in Teens in a Virtual World (Project AVATAR)
Updated: 4/5/2016
Eliciting Affect in Teens in a Virtual World (Project AVATAR)
Status: Enrolling
Updated: 4/5/2016
Click here to add this to my saved trials
Reducing High Risk Behavior in Treatment Court
Updated: 4/6/2016
Delivering HIV Risk Reduction Services in Treatment Court
Status: Enrolling
Updated: 4/6/2016
Reducing High Risk Behavior in Treatment Court
Updated: 4/6/2016
Delivering HIV Risk Reduction Services in Treatment Court
Status: Enrolling
Updated: 4/6/2016
Click here to add this to my saved trials
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Updated: 4/7/2016
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated: 4/7/2016
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Updated: 4/7/2016
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated: 4/7/2016
Click here to add this to my saved trials
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Updated: 4/7/2016
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated: 4/7/2016
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Updated: 4/7/2016
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated: 4/7/2016
Click here to add this to my saved trials
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Updated: 4/7/2016
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated: 4/7/2016
ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment
Updated: 4/7/2016
Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)
Status: Enrolling
Updated: 4/7/2016
Click here to add this to my saved trials
Applying the Use of Motivational Tools to Auditory Rehabilitation
Updated: 4/8/2016
Applying the Use of Motivational Tools to Auditory Rehabilitation
Status: Enrolling
Updated: 4/8/2016
Applying the Use of Motivational Tools to Auditory Rehabilitation
Updated: 4/8/2016
Applying the Use of Motivational Tools to Auditory Rehabilitation
Status: Enrolling
Updated: 4/8/2016
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Updated: 4/12/2016
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status: Enrolling
Updated: 4/12/2016
Click here to add this to my saved trials
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
Updated: 4/19/2016
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
Status: Enrolling
Updated: 4/19/2016
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
Updated: 4/19/2016
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
Status: Enrolling
Updated: 4/19/2016
Click here to add this to my saved trials
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Updated: 4/20/2016
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Status: Enrolling
Updated: 4/20/2016
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Updated: 4/20/2016
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Status: Enrolling
Updated: 4/20/2016
Click here to add this to my saved trials
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
Updated: 4/20/2016
A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption
Status: Enrolling
Updated: 4/20/2016
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
Updated: 4/20/2016
A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption
Status: Enrolling
Updated: 4/20/2016
Click here to add this to my saved trials
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
Updated: 4/20/2016
A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption
Status: Enrolling
Updated: 4/20/2016
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
Updated: 4/20/2016
A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption
Status: Enrolling
Updated: 4/20/2016
Click here to add this to my saved trials
Redirected MazF‐CD4 Autologous T Cells for HIV Gene Therapy
Updated: 5/3/2016
A Phase I, Open Label, Dual Cohort, Single Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Autologous CD4 T Cells Modified With a Retroviral Vector Expressing the MazF Endoribonuclease Gene in Patients With HIV
Status: Enrolling
Updated: 5/3/2016
Redirected MazF‐CD4 Autologous T Cells for HIV Gene Therapy
Updated: 5/3/2016
A Phase I, Open Label, Dual Cohort, Single Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Autologous CD4 T Cells Modified With a Retroviral Vector Expressing the MazF Endoribonuclease Gene in Patients With HIV
Status: Enrolling
Updated: 5/3/2016
Click here to add this to my saved trials